{"id":525,"date":"2022-04-21T19:03:20","date_gmt":"2022-04-22T00:03:20","guid":{"rendered":"https:\/\/nuvaira.com\/about-us\/"},"modified":"2023-03-29T10:27:15","modified_gmt":"2023-03-29T15:27:15","slug":"about-us","status":"publish","type":"page","link":"https:\/\/nuvaira.com\/fr\/about-us\/","title":{"rendered":"Qui sommes-nous"},"content":{"rendered":"<div class=\"nuvairaBlock context-purple\">\n    <div class=\"pageHeroBlok\">\n        <div class=\"container\">\n\n            <h1 class=\"pageHeroBlok__title\">Qui sommes-nous<\/h1>\n                            <div class=\"pageHeroBlok__description | wysiwyg\">\n                    <p><span style=\"font-weight: 400;\">Chez Nuvaira, notre mission est de transformer la prise en charge des maladies pulmonaires obstructives et d\u2019am\u00e9liorer de fa\u00e7on significative les r\u00e9sultats chez les patients atteints de ces pathologies. <\/span><\/p>\n                <\/div>\n            \n                        \n            \n            \n\n        <\/div>\n    <\/div>\n<\/div>\n\n<div class=\"nuvairaBlock | --space-top-none --space-bot-none\">\n<div class=\"halfPageMediaBlok halfPageMediaBlok--left\">\n\n    <div class=\"halfPageMediaBlok__media\">\n            <div class=\"media  media--square media--fluid\">\n\n        <img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"731\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/06\/Nuvaira-273-1024x731.jpg\" class=\"attachment-large size-large\" alt=\"\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/06\/Nuvaira-273-1024x731.jpg 1024w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/06\/Nuvaira-273-300x214.jpg 300w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/06\/Nuvaira-273-768x549.jpg 768w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/06\/Nuvaira-273-1536x1097.jpg 1536w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/06\/Nuvaira-273-2048x1463.jpg 2048w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/06\/Nuvaira-273-1600x1143.jpg 1600w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/>\n            <\/div>\n\n    \n            <div class=\"media media--4-5\"><\/div>\n\n                    <div class=\"halfPageMediaBlok__dots --position-bottom-left c-orange\">\n                <div class=\"logoDots\">\n    <svg width=\"276\" height=\"128\" viewBox=\"0 0 276 128\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n        <path class=\"path-0\" d=\"M207.1 29.4507C207.1 32.2756 206.262 35.037 204.693 37.3858C203.123 39.7346 200.893 41.5652 198.283 42.6462C195.673 43.7273 192.801 44.0101 190.031 43.459C187.26 42.9079 184.715 41.5476 182.718 39.5501C180.72 37.5526 179.36 35.0077 178.809 32.2371C178.258 29.4665 178.541 26.5948 179.622 23.9849C180.703 21.3751 182.533 19.1445 184.882 17.575C187.231 16.0056 189.992 15.168 192.817 15.168C196.605 15.168 200.238 16.6728 202.917 19.3513C205.595 22.0298 207.1 25.6627 207.1 29.4507Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-1\" d=\"M187.732 76.212C187.738 78.2019 187.153 80.1488 186.051 81.8061C184.95 83.4634 183.381 84.7566 181.545 85.522C179.708 86.2874 177.685 86.4907 175.733 86.1059C173.78 85.7212 171.986 84.7658 170.577 83.3607C169.168 81.9556 168.207 80.164 167.817 78.2128C167.427 76.2615 167.624 74.2383 168.384 72.3993C169.145 70.5603 170.433 68.9883 172.088 67.8821C173.742 66.776 175.687 66.1856 177.677 66.1855C180.339 66.1855 182.892 67.241 184.777 69.1205C186.662 71 187.724 73.5502 187.732 76.212Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-2\" d=\"M241.265 49.1612C241.27 51.1511 240.685 53.098 239.584 54.7553C238.483 56.4126 236.914 57.7058 235.077 58.4712C233.24 59.2367 231.218 59.4399 229.266 59.0551C227.313 58.6704 225.519 57.715 224.11 56.3099C222.701 54.9048 221.74 53.1132 221.35 51.162C220.96 49.2107 221.157 47.1875 221.917 45.3485C222.677 43.5096 223.966 41.9375 225.62 40.8313C227.274 39.7252 229.22 39.1348 231.21 39.1348C233.871 39.1348 236.425 40.1902 238.309 42.0697C240.194 43.9492 241.257 46.4994 241.265 49.1612Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-3\" d=\"M174.107 112.177C174.107 113.555 173.698 114.903 172.932 116.049C172.166 117.195 171.077 118.088 169.804 118.616C168.53 119.143 167.129 119.281 165.777 119.013C164.425 118.744 163.183 118.08 162.208 117.105C161.233 116.13 160.569 114.888 160.3 113.536C160.032 112.184 160.17 110.783 160.697 109.509C161.225 108.236 162.118 107.147 163.264 106.381C164.41 105.615 165.758 105.207 167.137 105.207C168.983 105.214 170.751 105.951 172.057 107.256C173.362 108.562 174.099 110.33 174.107 112.177Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-4\" d=\"M216.384 91.0369C216.384 92.4154 215.975 93.763 215.209 94.9092C214.443 96.0554 213.355 96.9487 212.081 97.4763C210.808 98.0038 209.406 98.1418 208.054 97.8729C206.702 97.604 205.46 96.9401 204.485 95.9654C203.511 94.9906 202.847 93.7487 202.578 92.3966C202.309 91.0446 202.447 89.6432 202.974 88.3696C203.502 87.096 204.395 86.0074 205.542 85.2415C206.688 84.4757 208.035 84.0669 209.414 84.0669C211.262 84.0669 213.035 84.8012 214.342 86.1083C215.65 87.4155 216.384 89.1883 216.384 91.0369Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-5\" d=\"M195.559 122.832C195.559 123.803 195.271 124.753 194.731 125.561C194.191 126.369 193.423 126.999 192.526 127.371C191.628 127.743 190.64 127.84 189.687 127.651C188.734 127.461 187.858 126.993 187.171 126.306C186.484 125.619 186.016 124.743 185.827 123.79C185.637 122.837 185.734 121.849 186.106 120.952C186.478 120.054 187.108 119.286 187.916 118.746C188.724 118.207 189.674 117.918 190.645 117.918C191.949 117.918 193.198 118.436 194.12 119.358C195.041 120.279 195.559 121.529 195.559 122.832Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-6\" d=\"M234.522 109.006C234.522 109.979 234.233 110.93 233.692 111.738C233.151 112.547 232.382 113.177 231.482 113.548C230.583 113.919 229.593 114.014 228.639 113.822C227.686 113.63 226.81 113.16 226.124 112.47C225.438 111.78 224.973 110.901 224.786 109.947C224.6 108.992 224.701 108.003 225.078 107.106C225.454 106.208 226.088 105.443 226.9 104.906C227.711 104.37 228.664 104.087 229.637 104.092C230.935 104.1 232.178 104.621 233.093 105.541C234.008 106.462 234.522 107.707 234.522 109.006Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-7\" d=\"M276 92.8093C276 93.781 275.712 94.7309 275.172 95.5389C274.632 96.3469 273.865 96.9766 272.967 97.3485C272.069 97.7204 271.082 97.8177 270.129 97.6281C269.176 97.4385 268.3 96.9706 267.613 96.2835C266.926 95.5963 266.458 94.7209 266.268 93.7678C266.079 92.8147 266.176 91.8268 266.548 90.929C266.92 90.0313 267.549 89.2639 268.357 88.724C269.165 88.1842 270.115 87.896 271.087 87.896C272.39 87.896 273.64 88.4136 274.561 89.3351C275.483 90.2565 276 91.5062 276 92.8093Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-8\" d=\"M262.175 71.4138C262.18 72.7992 261.775 74.1551 261.009 75.3098C260.243 76.4644 259.152 77.3659 257.874 77.9C256.596 78.434 255.188 78.5767 253.828 78.3099C252.469 78.0431 251.219 77.3788 250.237 76.4012C249.256 75.4236 248.586 74.1766 248.314 72.8183C248.042 71.4599 248.179 70.0513 248.707 68.7708C249.236 67.4903 250.133 66.3956 251.285 65.6253C252.436 64.855 253.791 64.4439 255.176 64.4438C257.027 64.4438 258.803 65.1773 260.115 66.4836C261.426 67.7899 262.167 69.5626 262.175 71.4138Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-9\" d=\"M117.518 20.4814C117.518 24.5323 118.72 28.4922 120.97 31.8603C123.221 35.2285 126.419 37.8536 130.162 39.4038C133.904 40.954 138.022 41.3596 141.995 40.5693C145.968 39.779 149.618 37.8284 152.482 34.964C155.347 32.0996 157.297 28.4502 158.088 24.4772C158.878 20.5042 158.472 16.386 156.922 12.6435C155.372 8.90104 152.747 5.70227 149.379 3.45174C146.01 1.20122 142.051 0 138 0C132.568 0 127.358 2.15786 123.517 5.99887C119.676 9.83989 117.518 15.0494 117.518 20.4814Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-10\" d=\"M68.8997 29.4507C68.8997 32.2756 69.7373 35.037 71.3067 37.3858C72.8761 39.7346 75.1068 41.5652 77.7166 42.6462C80.3264 43.7273 83.1982 44.0101 85.9688 43.459C88.7393 42.9079 91.2843 41.5476 93.2818 39.5501C95.2792 37.5526 96.6395 35.0077 97.1906 32.2371C97.7417 29.4665 97.4589 26.5948 96.3779 23.9849C95.2968 21.3751 93.4662 19.1445 91.1174 17.575C88.7686 16.0056 86.0072 15.168 83.1824 15.168C79.3944 15.168 75.7615 16.6728 73.083 19.3513C70.4044 22.0298 68.8997 25.6627 68.8997 29.4507Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-11\" d=\"M88.2671 76.212C88.2615 78.2019 88.8464 80.1488 89.9478 81.8061C91.0492 83.4634 92.6176 84.7566 94.4545 85.522C96.2913 86.2874 98.3139 86.4907 100.266 86.1059C102.219 85.7212 104.013 84.7658 105.422 83.3607C106.831 81.9556 107.792 80.164 108.182 78.2128C108.572 76.2615 108.375 74.2383 107.615 72.3993C106.854 70.5603 105.566 68.9883 103.911 67.8821C102.257 66.776 100.312 66.1856 98.3222 66.1855C95.6604 66.1855 93.1071 67.241 91.2223 69.1205C89.3374 71 88.2747 73.5502 88.2671 76.212Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-12\" d=\"M34.7354 49.1612C34.7297 51.1511 35.3147 53.098 36.4161 54.7553C37.5175 56.4126 39.0859 57.7058 40.9227 58.4712C42.7595 59.2367 44.7822 59.4399 46.7345 59.0551C48.6869 58.6704 50.4812 57.715 51.8902 56.3099C53.2993 54.9048 54.2598 53.1132 54.6501 51.162C55.0404 49.2107 54.843 47.1875 54.0828 45.3485C53.3226 43.5096 52.0338 41.9375 50.3797 40.8313C48.7255 39.7252 46.7803 39.1348 44.7904 39.1348C42.1286 39.1348 39.5754 40.1902 37.6905 42.0697C35.8057 43.9492 34.743 46.4994 34.7354 49.1612Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-13\" d=\"M101.893 112.177C101.893 113.555 102.302 114.903 103.068 116.049C103.834 117.195 104.922 118.088 106.196 118.616C107.47 119.143 108.871 119.281 110.223 119.013C111.575 118.744 112.817 118.08 113.792 117.105C114.767 116.13 115.43 114.888 115.699 113.536C115.968 112.184 115.83 110.783 115.303 109.509C114.775 108.236 113.882 107.147 112.736 106.381C111.589 105.615 110.242 105.207 108.863 105.207C107.017 105.214 105.249 105.951 103.943 107.256C102.638 108.562 101.901 110.33 101.893 112.177Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-14\" d=\"M59.616 91.0369C59.616 92.4154 60.0247 93.763 60.7906 94.9092C61.5565 96.0554 62.6451 96.9487 63.9187 97.4763C65.1923 98.0038 66.5937 98.1418 67.9457 97.8729C69.2977 97.604 70.5397 96.9401 71.5145 95.9654C72.4892 94.9906 73.153 93.7487 73.422 92.3966C73.6909 91.0446 73.5529 89.6432 73.0253 88.3696C72.4978 87.096 71.6045 86.0074 70.4583 85.2415C69.3121 84.4757 67.9645 84.0669 66.5859 84.0669C64.7374 84.0669 62.9646 84.8012 61.6574 86.1083C60.3503 87.4155 59.616 89.1883 59.616 91.0369Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-15\" d=\"M80.4409 122.832C80.4409 123.805 80.7298 124.756 81.271 125.564C81.8121 126.373 82.5812 127.003 83.4806 127.374C84.38 127.745 85.3694 127.84 86.3232 127.648C87.2771 127.457 88.1525 126.986 88.8385 126.296C89.5244 125.606 89.9901 124.728 90.1765 123.773C90.3628 122.818 90.2614 121.829 89.8852 120.932C89.5089 120.034 88.8747 119.269 88.063 118.733C87.2512 118.196 86.2985 117.913 85.3256 117.919C84.0275 117.926 82.7851 118.447 81.8699 119.368C80.9546 120.288 80.4409 121.534 80.4409 122.832Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-16\" d=\"M41.4766 109.006C41.4766 109.977 41.7647 110.927 42.3046 111.735C42.8445 112.543 43.6119 113.173 44.5096 113.545C45.4074 113.917 46.3953 114.014 47.3483 113.824C48.3014 113.635 49.1769 113.167 49.864 112.48C50.5512 111.793 51.0191 110.917 51.2086 109.964C51.3982 109.011 51.301 108.023 50.9291 107.125C50.5572 106.228 49.9274 105.46 49.1195 104.92C48.3115 104.38 47.3616 104.092 46.3898 104.092C45.0867 104.092 43.8371 104.61 42.9156 105.531C41.9942 106.453 41.4766 107.702 41.4766 109.006Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-17\" d=\"M0 92.8093C0 93.781 0.288155 94.7309 0.828032 95.5389C1.36791 96.3469 2.13525 96.9766 3.03304 97.3485C3.93082 97.7204 4.91872 97.8177 5.8718 97.6281C6.82488 97.4385 7.70032 96.9706 8.38745 96.2835C9.07459 95.5963 9.54255 94.7209 9.73213 93.7678C9.92171 92.8147 9.82439 91.8268 9.45251 90.929C9.08064 90.0313 8.45092 89.2639 7.64294 88.724C6.83495 88.1842 5.88502 87.896 4.91327 87.896C3.61019 87.896 2.36046 88.4136 1.43904 89.3351C0.517625 90.2565 0 91.5062 0 92.8093Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-18\" d=\"M13.855 71.4138C13.855 72.7923 14.2638 74.1399 15.0297 75.2861C15.7955 76.4323 16.8841 77.3257 18.1576 77.8532C19.4312 78.3808 20.8327 78.5188 22.1847 78.2499C23.5368 77.9809 24.7787 77.3171 25.7534 76.3423C26.7282 75.3676 27.392 74.1256 27.6609 72.7736C27.9299 71.4216 27.7919 70.0201 27.2643 68.7465C26.7368 67.4729 25.8434 66.3844 24.6972 65.6185C23.551 64.8526 22.2034 64.4438 20.8249 64.4438C18.9764 64.4438 17.2035 65.1782 15.8964 66.4853C14.5893 67.7924 13.855 69.5653 13.855 71.4138Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-19\" d=\"M123.66 69.5845C123.66 72.4093 124.498 75.1708 126.067 77.5196C127.637 79.8683 129.867 81.699 132.477 82.78C135.087 83.861 137.959 84.1439 140.729 83.5928C143.5 83.0417 146.045 81.6814 148.042 79.6839C150.04 77.6864 151.4 75.1415 151.951 72.3709C152.502 69.6003 152.219 66.7286 151.138 64.1187C150.057 61.5089 148.227 59.2782 145.878 57.7088C143.529 56.1394 140.768 55.3018 137.943 55.3018C134.155 55.3018 130.522 56.8065 127.843 59.4851C125.165 62.1636 123.66 65.7965 123.66 69.5845Z\" fill=\"#F47B20\"\/>\n        <path class=\"path-20\" d=\"M127.916 107.206C127.916 109.201 128.508 111.15 129.616 112.808C130.724 114.467 132.298 115.759 134.141 116.522C135.984 117.285 138.011 117.485 139.967 117.096C141.923 116.707 143.72 115.747 145.13 114.336C146.54 112.926 147.501 111.129 147.89 109.173C148.279 107.217 148.079 105.19 147.316 103.347C146.553 101.505 145.26 99.93 143.602 98.822C141.944 97.714 139.994 97.1226 138 97.1226C135.326 97.1226 132.761 98.1849 130.87 100.076C128.979 101.967 127.916 104.532 127.916 107.206Z\" fill=\"#F47B20\"\/>\n    <\/svg>\n<\/div>\n            <\/div>\n            <\/div>\n\n    <div class=\"halfPageMediaBlok__content\">\n\n        <div>\n\n                <div class=\"sectionHeading\">\n        <div class=\"sectionHeading__content\">\n                            <p class=\"label\">Pr\u00e9sentation de la soci\u00e9t\u00e9<\/p>\n                                        <h2 class=\"h-2\">L\u2019 innovation \u00e0 coeur<\/h2>\n                    <\/div>\n    <\/div>\n\n            <div class=\"mt-32 wysiwyg\">\n            <p>Nuvaira, Inc. d\u00e9veloppe des traitements innovants et r\u00e9volutionnaires qui visent \u00e0 am\u00e9liorer la vie des personnes atteintes de maladies pulmonaires obstructives pr\u00e9sentes chez plus de 65\u00a0millions d\u2019individus dans le monde entier. La soci\u00e9t\u00e9 a \u00e9t\u00e9 fond\u00e9e en\u00a02008 pour r\u00e9pondre aux besoins cliniques non couverts dans le traitement de l\u2019hyperactivit\u00e9 des nerfs bronchiques, une caract\u00e9ristique fr\u00e9quente de la BPCO et de l\u2019asthme.<\/p>\n<p>Nuvaira est une soci\u00e9t\u00e9 priv\u00e9e de dispositifs m\u00e9dicaux dont le si\u00e8ge social se situe \u00e0 Minneapolis, dans le Minnesota aux \u00c9tats-Unis. La soci\u00e9t\u00e9 d\u00e9tient plus de 70\u00a0brevets accord\u00e9s et en instance dans le monde entier.<\/p>\n        <\/div>\n    \n        \n        <\/div>\n    <\/div>\n\n<\/div>\n\n\n<\/div><!-- Nuvaira Block End -->\n\n\n<div class=\"nuvairaBlock | --space-top-large --space-bot-large --bg-purple context-purple --previous-none\">    <div class=\"container\">\n        <div class=\"twoCols twoCols--top \">\n\n            <div class=\"twoCols__col\">\n                <div class=\"sectionHeading\">\n                    <div class=\"sectionHeading__content\">\n                                                    <p class=\"label\">Syst\u00e8me de d\u00e9nervation des poumons dNerva\u00ae <\/p>\n                                                <h2 class=\"h-2\">\n                            Une solution simple et rapide. Une sant\u00e9 pulmonaire durable.                        <\/h2>\n                    <\/div>\n                <\/div>\n            <\/div>\n\n            <div class=\"twoCols__col\">\n                <div class=\"wysiwyg\">\n                    <p><span style=\"font-weight: 400;\">Le syst\u00e8me de d\u00e9nervation des poumons dNerva est un syst\u00e8me innovant qui utilise un cath\u00e9ter pour traiter l\u2019hyperactivit\u00e9 des nerfs bronchiques au cours d\u2019une intervention appel\u00e9e la D\u00e9nervation Cibl\u00e9e des Poumons (DCP). Cette technologie unique traite la physiopathologie sous-jacente de la BPCO pour aider \u00e0 pr\u00e9server la sant\u00e9 pulmonaire.<\/span><\/p>\n                <\/div>\n\n                                    <div class=\"mt-24\">\n                            <a class=\"btn btn--translucent\" href=\"https:\/\/nuvaira.com\/fr\/technology\/\" >\n        En savoir plus <i class=\"far fa-arrow-right\"><\/i>\n    <\/a>\n                        <\/div>\n                            <\/div>\n        <\/div>\n    <\/div>\n<\/div><!-- Nuvaira Block End -->\n\n\n<div class=\"nuvairaBlock | --space-top-regular --space-bot-regular --bg-white context-white --previous-large\">\n    <div class=\"container\">\n        <div class=\"sectionHeading sectionHeading--no-ornament  sectionHeading--center\">\n\n            <div class=\"sectionHeading__content\">\n\n                \n                                    <h2 class=\"h-2\">Historique de la soci\u00e9t\u00e9 <\/h2>\n                \n                \n            <\/div>\n\n            \n        <\/div>\n    <\/div>\n\n<\/div><!-- Nuvaira Block End -->\n\n\n\n<div class=\"nuvairaBlock | --space-top-none --space-bot-none --bg-white context-white --previous-regular\">\n<div class=\"container\">\n    <div class=\"timelineBlok timelineBlok--front\">\n            <div class=\"timelineBlok__entry\">\n            <div class=\"timelineBlok__date\">2022<\/div>\n            <div class=\"timelineBlok__content\">\n                <div class=\"wysiwyg\">\n                    <p><strong>Les \u00e9tapes importantes du d\u00e9veloppement<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">300\u00a0patients ont b\u00e9n\u00e9fici\u00e9 d\u2019un traitement par le syst\u00e8me de d\u00e9nervation des poumons dNerva dans le cadre de 5\u00a0essais cliniques \u00e0 l\u2019\u00e9chelle internationale.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Nuvaira cl\u00f4ture un cycle de financement de 50\u00a0millions de dollars pour la poursuite du d\u00e9veloppement de ce traitement r\u00e9volutionnaire de la BPCO.<\/span><\/li>\n<\/ul>\n                <\/div>\n            <\/div>\n        <\/div>\n            <div class=\"timelineBlok__entry\">\n            <div class=\"timelineBlok__date\">2020 &#8211; 2021<\/div>\n            <div class=\"timelineBlok__content\">\n                <div class=\"wysiwyg\">\n                    <p><strong>R\u00e9sultats de l\u2019\u00e9tude AIRFLOW-2 \u00e0 deux ans<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Publication des r\u00e9sultats de l\u2019\u00e9tude AIRFLOW-2 indiquant une r\u00e9duction du risque d\u2019exacerbations s\u00e9v\u00e8res chez les patients trait\u00e9s par le syst\u00e8me de d\u00e9nervation des poumons dNerva.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Le syst\u00e8me de d\u00e9nervation des poumons dNerva est d\u00e9sign\u00e9 en tant que \u00ab\u00a0breakthrough device\u00a0\u00bb (Dispositif innovant) par la Food and Drug Administration (FDA) des \u00c9tats-Unis.<\/span><\/li>\n<\/ul>\n                <\/div>\n            <\/div>\n        <\/div>\n            <div class=\"timelineBlok__entry\">\n            <div class=\"timelineBlok__date\">2019<\/div>\n            <div class=\"timelineBlok__content\">\n                <div class=\"wysiwyg\">\n                    <p><strong>D\u00e9but de l\u2019essai pivot <\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Premiers patients trait\u00e9s dans le cadre de l\u2019essai pivot AIRFLOW-3.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Le syst\u00e8me de d\u00e9nervation des poumons dNerva est le premier dispositif pulmonaire dont la candidature au programme \u00ab\u00a0Forfait innovation\u00a0\u00bb de la HAS (Haute Autorit\u00e9 de Sant\u00e9) a \u00e9t\u00e9 retenue.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Nuvaira cl\u00f4ture un cycle de financement de 79\u00a0millions de dollars pour la poursuite du d\u00e9veloppement de ce traitement r\u00e9volutionnaire de la BPCO.<\/span><\/li>\n<\/ul>\n                <\/div>\n            <\/div>\n        <\/div>\n            <div class=\"timelineBlok__entry\">\n            <div class=\"timelineBlok__date\">2018<\/div>\n            <div class=\"timelineBlok__content\">\n                <div class=\"wysiwyg\">\n                    <p><strong>Confirmation de la s\u00e9curit\u00e9 de la <\/strong><strong>D\u00e9nervation Cibl\u00e9e des Poumons <\/strong><strong>\u00e0 long terme\u00a0<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Les r\u00e9sultats de l\u2019\u00e9tude confirment que la DCP est un traitement r\u00e9alisable et s\u00fbr chez les patients atteints de BPCO mod\u00e9r\u00e9e \u00e0 s\u00e9v\u00e8re sur 3\u00a0ans.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">La FDA approuve l\u2019essai pivot AIRFLOW-3.<\/span><\/li>\n<\/ul>\n                <\/div>\n            <\/div>\n        <\/div>\n            <div class=\"timelineBlok__entry\">\n            <div class=\"timelineBlok__date\">2016 &#8211; 2017<\/div>\n            <div class=\"timelineBlok__content\">\n                <div class=\"wysiwyg\">\n                    <p><strong>Essai clinique AIRFLOW-2\u00a0<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Recrutement et r\u00e9alisation de l\u2019\u00e9tude de s\u00e9curit\u00e9 et de faisabilit\u00e9 AIRFLOW-2.<\/span><\/li>\n<\/ul>\n                <\/div>\n            <\/div>\n        <\/div>\n            <div class=\"timelineBlok__entry\">\n            <div class=\"timelineBlok__date\">2014 &#8211; 2015<\/div>\n            <div class=\"timelineBlok__content\">\n                <div class=\"wysiwyg\">\n                    <p><strong>Essai clinique AIRFLOW-1\u00a0<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Recrutement et r\u00e9alisation de l\u2019\u00e9tude de s\u00e9curit\u00e9 et de d\u00e9termination de dose AIRFLOW-1.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Nuvaira cl\u00f4ture un cycle de financement de 49\u00a0millions de dollars pour la poursuite du d\u00e9veloppement de ce traitement r\u00e9volutionnaire de la BPCO. <\/span><\/li>\n<\/ul>\n                <\/div>\n            <\/div>\n        <\/div>\n            <div class=\"timelineBlok__entry\">\n            <div class=\"timelineBlok__date\">2012 &#8211; 2013<\/div>\n            <div class=\"timelineBlok__content\">\n                <div class=\"wysiwyg\">\n                    <p><strong>Premi\u00e8re intervention chez l\u2019\u00eatre humain<\/strong><\/p>\n<ul>\n<li><span style=\"font-weight: 400\">Nuvaira r\u00e9alise sa premi\u00e8re intervention chez l\u2019\u00eatre humain en janvier\u00a02012 et confirme la faisabilit\u00e9 et la s\u00e9curit\u00e9 d\u2019un traitement unique des deux poumons.\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li><span style=\"font-weight: 400\">Nuvaira d\u00e9veloppe son cath\u00e9ter dNerva de 2\u00e8me\u00a0g\u00e9n\u00e9ration.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n                <\/div>\n            <\/div>\n        <\/div>\n            <div class=\"timelineBlok__entry\">\n            <div class=\"timelineBlok__date\">2010 &#8211; 2011<\/div>\n            <div class=\"timelineBlok__content\">\n                <div class=\"wysiwyg\">\n                    <p><strong>Cr\u00e9ation du cath\u00e9ter dNerva<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Nuvaira d\u00e9veloppe son cath\u00e9ter dNerva de 1\u00e8re g\u00e9n\u00e9ration dans le cadre de son programme <\/span><i><span style=\"font-weight: 400\">ex\u00a0vivo<\/span><\/i><span style=\"font-weight: 400\">.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Nuvaira ach\u00e8ve plus de 10\u00a0\u00e9tudes pr\u00e9cliniques, plus de 65\u00a0\u00e9tudes chez l\u2019animal et traite plus de 130\u00a0voies respiratoires.<\/span><\/li>\n<\/ul>\n                <\/div>\n            <\/div>\n        <\/div>\n            <div class=\"timelineBlok__entry\">\n            <div class=\"timelineBlok__date\">2008<\/div>\n            <div class=\"timelineBlok__content\">\n                <div class=\"wysiwyg\">\n                    <p><strong>Fondation de la soci\u00e9t\u00e9\u00a0<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Nuvaira est fond\u00e9e par le Dr Martin Mayse et M. Steve Dimmer.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">La propri\u00e9t\u00e9 intellectuelle est enregistr\u00e9e d\u00e9but\u00a02008\u00a0; les premiers essais chez l\u2019animal et le d\u00e9veloppement de la preuve de concept d\u00e9butent. <\/span><\/li>\n<\/ul>\n                <\/div>\n            <\/div>\n        <\/div>\n        <\/div>\n<\/div>\n\n<\/div><!-- Nuvaira Block End -->\n\n<div class=\"jumpToSectionBlok\" id=\"section-leadership\">\n    <\/div>\n\n\n<div class=\"nuvairaBlock | --space-top-regular --space-bot-small --bg-white context-white --previous-none\">\n    <div class=\"container\">\n        <div class=\"sectionHeading sectionHeading--no-ornament  sectionHeading--left\">\n\n            <div class=\"sectionHeading__content\">\n\n                \n                                    <h2 class=\"h-2\">\u00c9quipe de direction<\/h2>\n                \n                \n            <\/div>\n\n            \n        <\/div>\n    <\/div>\n\n<\/div><!-- Nuvaira Block End -->\n\n\n\n\n<div class=\"nuvairaBlock | --space-top-none --space-bot-regular --bg-white context-white --previous-small\"><div class=\"container\">\n\n    <div class=\"personCardsBlok\">\n\n                    <div class=\"personCardsBlok__item\">\n\n                <div class=\"personCardsBlok__clickable\" data-target=\"#person-1-0\">\n                                            <div class=\"personCardsBlok__image | object-fit-cover\">\n                            <img loading=\"lazy\" decoding=\"async\" width=\"384\" height=\"384\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/01-dennis-wahr.jpg\" class=\"attachment-medium_large size-medium_large\" alt=\"\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/01-dennis-wahr.jpg 384w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/01-dennis-wahr-300x300.jpg 300w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/01-dennis-wahr-150x150.jpg 150w\" sizes=\"auto, (max-width: 384px) 100vw, 384px\" \/>                        <\/div>\n                                        \n                    <h3 class=\"personCardsBlok__name\">Dennis Wahr, M.D.<\/h3>\n                    <p class=\"personCardsBlok__position\">Pr\u00e9sident et PDG<\/p>\n                <\/div>\n\n            <\/div>\n                    <div class=\"personCardsBlok__item\">\n\n                <div class=\"personCardsBlok__clickable\" data-target=\"#person-1-1\">\n                                            <div class=\"personCardsBlok__image | object-fit-cover\">\n                            <img loading=\"lazy\" decoding=\"async\" width=\"384\" height=\"384\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/02-david-kressler.jpg\" class=\"attachment-medium_large size-medium_large\" alt=\"\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/02-david-kressler.jpg 384w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/02-david-kressler-300x300.jpg 300w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/02-david-kressler-150x150.jpg 150w\" sizes=\"auto, (max-width: 384px) 100vw, 384px\" \/>                        <\/div>\n                                        \n                    <h3 class=\"personCardsBlok__name\">David Kressler<\/h3>\n                    <p class=\"personCardsBlok__position\">Vice-pr\u00e9sident, Op\u00e9rations<\/p>\n                <\/div>\n\n            <\/div>\n                    <div class=\"personCardsBlok__item\">\n\n                <div class=\"personCardsBlok__clickable\" data-target=\"#person-1-2\">\n                                            <div class=\"personCardsBlok__image | object-fit-cover\">\n                            <img loading=\"lazy\" decoding=\"async\" width=\"384\" height=\"384\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/03-thomas-griffin.jpg\" class=\"attachment-medium_large size-medium_large\" alt=\"\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/03-thomas-griffin.jpg 384w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/03-thomas-griffin-300x300.jpg 300w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/03-thomas-griffin-150x150.jpg 150w\" sizes=\"auto, (max-width: 384px) 100vw, 384px\" \/>                        <\/div>\n                                        \n                    <h3 class=\"personCardsBlok__name\">Thomas E. Griffin<\/h3>\n                    <p class=\"personCardsBlok__position\">Directeur financier <\/p>\n                <\/div>\n\n            <\/div>\n                    <div class=\"personCardsBlok__item\">\n\n                <div class=\"personCardsBlok__clickable\" data-target=\"#person-1-3\">\n                                            <div class=\"personCardsBlok__image | object-fit-cover\">\n                            <img loading=\"lazy\" decoding=\"async\" width=\"384\" height=\"384\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/04-lisa-rogan.jpg\" class=\"attachment-medium_large size-medium_large\" alt=\"\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/04-lisa-rogan.jpg 384w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/04-lisa-rogan-300x300.jpg 300w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/04-lisa-rogan-150x150.jpg 150w\" sizes=\"auto, (max-width: 384px) 100vw, 384px\" \/>                        <\/div>\n                                        \n                    <h3 class=\"personCardsBlok__name\">Lisa Rogan<\/h3>\n                    <p class=\"personCardsBlok__position\">Vice-pr\u00e9sidente principale, D\u00e9veloppement des march\u00e9s internationaux<\/p>\n                <\/div>\n\n            <\/div>\n                    <div class=\"personCardsBlok__item\">\n\n                <div class=\"personCardsBlok__clickable\" data-target=\"#person-1-4\">\n                                            <div class=\"personCardsBlok__image | object-fit-cover\">\n                            <img loading=\"lazy\" decoding=\"async\" width=\"766\" height=\"768\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/05-john-carline.jpg\" class=\"attachment-medium_large size-medium_large\" alt=\"\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/05-john-carline.jpg 766w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/05-john-carline-300x300.jpg 300w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/05-john-carline-150x150.jpg 150w\" sizes=\"auto, (max-width: 766px) 100vw, 766px\" \/>                        <\/div>\n                                        \n                    <h3 class=\"personCardsBlok__name\">John Carline<\/h3>\n                    <p class=\"personCardsBlok__position\">Directeur principal, Affaires r\u00e9glementaires et qualit\u00e9<\/p>\n                <\/div>\n\n            <\/div>\n                    <div class=\"personCardsBlok__item\">\n\n                <div class=\"personCardsBlok__clickable\" data-target=\"#person-1-5\">\n                                            <div class=\"personCardsBlok__image | object-fit-cover\">\n                            <img loading=\"lazy\" decoding=\"async\" width=\"384\" height=\"384\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/06-philip-johnson.jpg\" class=\"attachment-medium_large size-medium_large\" alt=\"\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/06-philip-johnson.jpg 384w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/06-philip-johnson-300x300.jpg 300w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/06-philip-johnson-150x150.jpg 150w\" sizes=\"auto, (max-width: 384px) 100vw, 384px\" \/>                        <\/div>\n                                        \n                    <h3 class=\"personCardsBlok__name\">Philip Johnson, Ph.D.<\/h3>\n                    <p class=\"personCardsBlok__position\">Vice-pr\u00e9sident, Science et Recherche-d\u00e9veloppement<\/p>\n                <\/div>\n\n            <\/div>\n        \n\n    <\/div>\n\n<\/div>\n<\/div><!-- Nuvaira Block End -->\n<div class=\"personCardsBlok__overlay\">\n\n    <div class=\"personCardsBlok__close\">\n        <i class=\"fas fa-times\"><\/i>\n    <\/div>\n\n    \n    <div class=\"personCardsBlok__modal\" id=\"person-1-0\">\n        <div class=\"personCardsBlok__modalContent\">\n\n                            <div class=\"personCardsBlok__modalImage\">\n                    <div class=\"personCardsBlok__image object-fit-cover\">\n                        <img loading=\"lazy\" decoding=\"async\" width=\"384\" height=\"384\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/01-dennis-wahr.jpg\" class=\"attachment-medium_large size-medium_large\" alt=\"\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/01-dennis-wahr.jpg 384w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/01-dennis-wahr-300x300.jpg 300w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/01-dennis-wahr-150x150.jpg 150w\" sizes=\"auto, (max-width: 384px) 100vw, 384px\" \/>                    <\/div>\n                <\/div>\n            \n            <h3 class=\"personCardsBlok__name\">Dennis Wahr, M.D.<\/h3>\n            <p class=\"personCardsBlok__position\">Pr\u00e9sident et PDG<\/p>\n\n            <div class=\"sectionHeading__content | mt-24\">\n                <div class=\"wysiwyg personCardsBlok__bio\">\n                    <p><span style=\"font-weight: 400;\">Dennis Wahr a rejoint Nuvaira en tant que PDG en 2012 avec une exp\u00e9rience unique et diversifi\u00e9e en mati\u00e8re de d\u00e9veloppement de dispositifs m\u00e9dicaux, d\u2019\u00e9valuation clinique et de commercialisation.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Avant d\u2019int\u00e9grer Nuvaira, Dennis a co-fond\u00e9 la soci\u00e9t\u00e9 Lutonix en\u00a02007, o\u00f9 il a assum\u00e9 la fonction de pr\u00e9sident et PDG jusqu\u2019\u00e0 ce que CR\u00a0Bard rach\u00e8te l\u2019entreprise en d\u00e9cembre\u00a02011. Avant Lutonix, il a co-fond\u00e9 la soci\u00e9t\u00e9 Velocimed en\u00a02001 et exerc\u00e9 en qualit\u00e9 de pr\u00e9sident et PDG jusqu\u2019\u00e0 ce que St.\u00a0Jude Medical rach\u00e8te l\u2019entreprise en\u00a02005.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Dennis a si\u00e9g\u00e9 au conseil d\u2019administration de plusieurs soci\u00e9t\u00e9s de dispositifs m\u00e9dicaux, dont Accumetrics, IDev, Velocimed et Lutonix, et a \u00e9t\u00e9 nomm\u00e9 pr\u00e9sident du conseil d\u2019administration d\u2019Intact Vascular que Philips a rachet\u00e9 en\u00a02020.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Avant sa carri\u00e8re d\u2019entrepreneur dans le secteur des dispositifs m\u00e9dicaux, il a pratiqu\u00e9 en tant que cardiologue interventionnel agr\u00e9\u00e9 et occup\u00e9 la fonction de chef de Cardiologie au Michigan Heart and Vascular Institute \u00e0 Ann Arbor, MI.<\/span><\/p>\n                <\/div>\n            <\/div>\n\n        <\/div>\n\n    <\/div>\n    \n    <div class=\"personCardsBlok__modal\" id=\"person-1-1\">\n        <div class=\"personCardsBlok__modalContent\">\n\n                            <div class=\"personCardsBlok__modalImage\">\n                    <div class=\"personCardsBlok__image object-fit-cover\">\n                        <img loading=\"lazy\" decoding=\"async\" width=\"384\" height=\"384\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/02-david-kressler.jpg\" class=\"attachment-medium_large size-medium_large\" alt=\"\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/02-david-kressler.jpg 384w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/02-david-kressler-300x300.jpg 300w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/02-david-kressler-150x150.jpg 150w\" sizes=\"auto, (max-width: 384px) 100vw, 384px\" \/>                    <\/div>\n                <\/div>\n            \n            <h3 class=\"personCardsBlok__name\">David Kressler<\/h3>\n            <p class=\"personCardsBlok__position\">Vice-pr\u00e9sident, Op\u00e9rations<\/p>\n\n            <div class=\"sectionHeading__content | mt-24\">\n                <div class=\"wysiwyg personCardsBlok__bio\">\n                    <p><span style=\"font-weight: 400;\">David Kressler a int\u00e9gr\u00e9 Nuvaira en\u00a02019, apr\u00e8s plus de 20\u00a0ans d\u2019exp\u00e9rience en gestion des op\u00e9rations dans le secteur des dispositifs m\u00e9dicaux. Il a dirig\u00e9 avec succ\u00e8s des organisations de production de pointe au sein d\u2019entreprises multinationales de dispositifs m\u00e9dicaux, et mis sur pied des \u00e9quipes d\u2019op\u00e9rations dans plusieurs jeunes entreprises \u00e0 un stade pr\u00e9coce.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Avant de rejoindre Nuvaira, David a exerc\u00e9 en qualit\u00e9 de vice-pr\u00e9sident des op\u00e9rations chez CardioFocus, une start-up dans sa derni\u00e8re phase de financement qui fabrique un syst\u00e8me unique de cath\u00e9ter d\u2019ablation par laser \u00e0 ballonnet, utilis\u00e9 pour le traitement de la fibrillation auriculaire. Sous sa direction des op\u00e9rations, la soci\u00e9t\u00e9 a connu une forte croissance, et il a men\u00e9 \u00e0 bien la pr\u00e9paration \u00e0 la r\u00e9glementation et aux soumissions \u00e0 la FDA ainsi que les efforts de commercialisation internationale. David est intervenu comme consultant aupr\u00e8s de nombreuses grandes entreprises de dispositifs m\u00e9dicaux, se sp\u00e9cialisant en projets de croissance de capacit\u00e9, en logistique et en production all\u00e9g\u00e9e. Au d\u00e9but de sa carri\u00e8re, il a occup\u00e9 pendant 14\u00a0ans diverses fonctions \u00e0 responsabilit\u00e9 croissante au sein de Boston Scientific.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Il est titulaire d\u2019une licence en ing\u00e9nierie industrielle de Northeastern University et d\u2019une ma\u00eetrise en gestion de Lesley University.<\/span><\/p>\n                <\/div>\n            <\/div>\n\n        <\/div>\n\n    <\/div>\n    \n    <div class=\"personCardsBlok__modal\" id=\"person-1-2\">\n        <div class=\"personCardsBlok__modalContent\">\n\n                            <div class=\"personCardsBlok__modalImage\">\n                    <div class=\"personCardsBlok__image object-fit-cover\">\n                        <img loading=\"lazy\" decoding=\"async\" width=\"384\" height=\"384\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/03-thomas-griffin.jpg\" class=\"attachment-medium_large size-medium_large\" alt=\"\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/03-thomas-griffin.jpg 384w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/03-thomas-griffin-300x300.jpg 300w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/03-thomas-griffin-150x150.jpg 150w\" sizes=\"auto, (max-width: 384px) 100vw, 384px\" \/>                    <\/div>\n                <\/div>\n            \n            <h3 class=\"personCardsBlok__name\">Thomas E. Griffin<\/h3>\n            <p class=\"personCardsBlok__position\">Directeur financier <\/p>\n\n            <div class=\"sectionHeading__content | mt-24\">\n                <div class=\"wysiwyg personCardsBlok__bio\">\n                    <p><span style=\"font-weight: 400;\">Tom Griffin a rejoint Nuvaira en\u00a02020, apr\u00e8s avoir acquis une solide exp\u00e9rience dans le domaine des finances et dirig\u00e9 le financement en capital-risque et l\u2019introduction en bourse de plusieurs soci\u00e9t\u00e9s de dispositifs m\u00e9dicaux,<\/span> <span style=\"font-weight: 400;\">y compris des projets de commercialisation rapide et des fusions-acquisitions couronn\u00e9s de succ\u00e8s.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Avant d\u2019int\u00e9grer Nuvaira, Tom \u00e9tait directeur financier d\u2019Avedro, Inc., une soci\u00e9t\u00e9 hybride de premier plan \u0153uvrant dans le domaine des technologies ophtalmiques, pharmaceutiques et m\u00e9dicales. Avedro a r\u00e9alis\u00e9 son introduction en bourse en f\u00e9vrier\u00a02019 et a \u00e9t\u00e9 rachet\u00e9e par Glaukos Corporation en novembre\u00a02019.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Avant de rejoindre Avedro, Tom a occup\u00e9 le poste de directeur financier d\u2019Entellus Medical, Inc., une soci\u00e9t\u00e9 sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de produits con\u00e7us pour le traitement mini-invasif de sinusites chronique et r\u00e9currente. Entellus a r\u00e9alis\u00e9 son introduction en bourse en janvier\u00a02015, puis a \u00e9t\u00e9 rachet\u00e9e par Stryker Corporation en f\u00e9vrier\u00a02018.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Tom est titulaire d\u2019une licence en comptabilit\u00e9 de l\u2019University of Minnesota, Duluth et d\u2019un MBA en gestion de l\u2019University of St. Thomas. Il est \u00e9galement expert-comptable agr\u00e9\u00e9 (CPA) (inactif). <\/span><\/p>\n                <\/div>\n            <\/div>\n\n        <\/div>\n\n    <\/div>\n    \n    <div class=\"personCardsBlok__modal\" id=\"person-1-3\">\n        <div class=\"personCardsBlok__modalContent\">\n\n                            <div class=\"personCardsBlok__modalImage\">\n                    <div class=\"personCardsBlok__image object-fit-cover\">\n                        <img loading=\"lazy\" decoding=\"async\" width=\"384\" height=\"384\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/04-lisa-rogan.jpg\" class=\"attachment-medium_large size-medium_large\" alt=\"\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/04-lisa-rogan.jpg 384w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/04-lisa-rogan-300x300.jpg 300w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/04-lisa-rogan-150x150.jpg 150w\" sizes=\"auto, (max-width: 384px) 100vw, 384px\" \/>                    <\/div>\n                <\/div>\n            \n            <h3 class=\"personCardsBlok__name\">Lisa Rogan<\/h3>\n            <p class=\"personCardsBlok__position\">Vice-pr\u00e9sidente principale, D\u00e9veloppement des march\u00e9s internationaux<\/p>\n\n            <div class=\"sectionHeading__content | mt-24\">\n                <div class=\"wysiwyg personCardsBlok__bio\">\n                    <p><span style=\"font-weight: 400;\">Lisa Rogan a rejoint Nuvaira en\u00a02018 et apport\u00e9 ses 20\u00a0ans d\u2019expertise dans la commercialisation des technologies diagnostiques et th\u00e9rapeutiques dans le secteur des dispositifs m\u00e9dicaux, notamment dans les domaines de la pneumologie, du diab\u00e8te, de l\u2019imagerie ultrasonore et de la m\u00e9decine n\u00e9onatale.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Avant d\u2019int\u00e9grer Nuvaira, Lisa \u00e9tait vice-pr\u00e9sidente principale de la strat\u00e9gie de d\u00e9veloppement th\u00e9rapeutique chez PneumRx, Inc., o\u00f9 elle \u00e9tait charg\u00e9e du pilotage du programme clinique et du d\u00e9veloppement des strat\u00e9gies d\u2019acc\u00e8s aux march\u00e9s. Avant cela, elle a \u00e9t\u00e9 nomm\u00e9e vice-pr\u00e9sidente du marketing chez Pulmonx, Inc., o\u00f9 elle a r\u00e9introduit les valves endobronchiques pour le traitement de l\u2019emphys\u00e8me sur les march\u00e9s europ\u00e9ens. Lisa a \u00e9galement occup\u00e9 des postes de gestion des op\u00e9rations, du marketing et du d\u00e9veloppement de produits chez <\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><span style=\"font-weight: 400;\">Siemens Medical Solutions, Inc. et Natus Medical, Inc.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Elle est titulaire d\u2019une licence en commerce international de California State University, Fullerton, d\u2019un dipl\u00f4me d\u2019\u00e9tudes litt\u00e9raires de l\u2019Universit\u00e9 de Montpellier, France, et d\u2019un MBA de Haas School of Business \u00e0 l\u2019University of California, Berkeley.<\/span><\/p>\n                <\/div>\n            <\/div>\n\n        <\/div>\n\n    <\/div>\n    \n    <div class=\"personCardsBlok__modal\" id=\"person-1-4\">\n        <div class=\"personCardsBlok__modalContent\">\n\n                            <div class=\"personCardsBlok__modalImage\">\n                    <div class=\"personCardsBlok__image object-fit-cover\">\n                        <img loading=\"lazy\" decoding=\"async\" width=\"766\" height=\"768\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/05-john-carline.jpg\" class=\"attachment-medium_large size-medium_large\" alt=\"\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/05-john-carline.jpg 766w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/05-john-carline-300x300.jpg 300w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/05-john-carline-150x150.jpg 150w\" sizes=\"auto, (max-width: 766px) 100vw, 766px\" \/>                    <\/div>\n                <\/div>\n            \n            <h3 class=\"personCardsBlok__name\">John Carline<\/h3>\n            <p class=\"personCardsBlok__position\">Directeur principal, Affaires r\u00e9glementaires et qualit\u00e9<\/p>\n\n            <div class=\"sectionHeading__content | mt-24\">\n                <div class=\"wysiwyg personCardsBlok__bio\">\n                    <p><span style=\"font-weight: 400;\">John Carline a int\u00e9gr\u00e9 Nuvaira en\u00a02021 et apporte sa vaste exp\u00e9rience dans les domaines r\u00e9glementaires et qualit\u00e9, acquise au sein d\u2019entreprises de grande envergure et de start-ups. John compte plus de 20\u00a0ans d\u2019exp\u00e9rience dans le secteur des dispositifs m\u00e9dicaux et a connu des succ\u00e8s significatifs dans l\u2019obtention de nombreuses approbations de la FDA\u00a0\u2013 notamment des approbations pr\u00e9-march\u00e9 [PMA], des exemptions de dispositifs de recherche [IDE] et des notifications pr\u00e9-march\u00e9 [510(k)]\u00a0\u2013 d\u2019approbations r\u00e9glementaires internationales et la r\u00e9alisation d\u2019audits favorables des syst\u00e8mes de gestion de la qualit\u00e9.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Avant de rejoindre Nuvaira, John a exerc\u00e9 en tant que directeur principal des affaires r\u00e9glementaires chez Lutonix\/CR Bard\/Becton Dickinson, o\u00f9 ses responsabilit\u00e9s se sont multipli\u00e9es au fil des 12\u00a0ann\u00e9es pass\u00e9es au sein de ce groupe. Au d\u00e9but de sa carri\u00e8re, il a occup\u00e9 divers postes r\u00e9glementaires chez St.\u00a0Jude Medical, Velocimed, Cardiac Science et SurVivaLink.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">John d\u00e9tient une licence en ing\u00e9nierie \u00e9lectrique de l\u2019University of Minnesota et un MBA de Carlson School of Management \u00e0 l\u2019University of Minnesota.<\/span><\/p>\n                <\/div>\n            <\/div>\n\n        <\/div>\n\n    <\/div>\n    \n    <div class=\"personCardsBlok__modal\" id=\"person-1-5\">\n        <div class=\"personCardsBlok__modalContent\">\n\n                            <div class=\"personCardsBlok__modalImage\">\n                    <div class=\"personCardsBlok__image object-fit-cover\">\n                        <img loading=\"lazy\" decoding=\"async\" width=\"384\" height=\"384\" src=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/06-philip-johnson.jpg\" class=\"attachment-medium_large size-medium_large\" alt=\"\" srcset=\"https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/06-philip-johnson.jpg 384w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/06-philip-johnson-300x300.jpg 300w, https:\/\/nuvaira.com\/wp-content\/uploads\/2022\/04\/06-philip-johnson-150x150.jpg 150w\" sizes=\"auto, (max-width: 384px) 100vw, 384px\" \/>                    <\/div>\n                <\/div>\n            \n            <h3 class=\"personCardsBlok__name\">Philip Johnson, Ph.D.<\/h3>\n            <p class=\"personCardsBlok__position\">Vice-pr\u00e9sident, Science et Recherche-d\u00e9veloppement<\/p>\n\n            <div class=\"sectionHeading__content | mt-24\">\n                <div class=\"wysiwyg personCardsBlok__bio\">\n                    <p><span style=\"font-weight: 400;\">Philip Johnson a int\u00e9gr\u00e9 Nuvaira en\u00a02013 et poss\u00e8de 15\u00a0ans d\u2019exp\u00e9rience en recherche biom\u00e9dicale avec une expertise en l\u00e9sion des nerfs p\u00e9riph\u00e9riques, en innervation autonome du poumon et en th\u00e9rapies de neuromodulation.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Avant de rejoindre Nuvaira, Philip a occup\u00e9 le poste de directeur du Laboratoire de recherche sur les nerfs p\u00e9riph\u00e9riques et professeur adjoint de chirurgie \u00e0 Washington University School of Medicine. \u00c0 ce titre, Philip a dirig\u00e9 un laboratoire de recherche financ\u00e9 par le NIH, ax\u00e9 sur la science fondamentale des l\u00e9sions\/de la r\u00e9g\u00e9n\u00e9ration des nerfs p\u00e9riph\u00e9riques et sur le d\u00e9veloppement de techniques d\u2019ing\u00e9nierie tissulaire visant \u00e0 am\u00e9liorer les r\u00e9sultats suite \u00e0 une l\u00e9sion traumatique des nerfs. Il a publi\u00e9 plus de 35\u00a0manuscrits \u00e9valu\u00e9s par des pairs sur la l\u00e9sion des nerfs p\u00e9riph\u00e9riques et l\u2019ing\u00e9nierie tissulaire.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Philip d\u00e9tient une licence en ing\u00e9nierie biom\u00e9dicale de Saint Louis University, ainsi qu\u2019une ma\u00eetrise et un doctorat en ing\u00e9nierie biom\u00e9dicale de Washington University \u00e0 St. Louis.<\/span><\/p>\n                <\/div>\n            <\/div>\n\n        <\/div>\n\n    <\/div>\n    <\/div>\n\n\n\n<div class=\"nuvairaBlock | --space-top-none --space-bot-regular --bg-white context-white --previous-regular\">\n<div class=\"container\">\n\n            <h3 class=\"h-3 | mb-48\">Board of Directors<\/h3>\n    \n    <div class=\"personListBlok\">\n\n                    <div class=\"personListBlok__item\">\n                <div class=\"sectionHeading__content\">\n                    <h4 class=\"personCardsBlok__name\">Jon Root<\/h4>\n                    <p class=\"personCardsBlok__position\">Partenaire associ\u00e9<\/p>\n\n                                            <a class=\"personListBlok__link\" href=\"https:\/\/www.usvp.com\/team\/jon-root\/\" target=\"_blank\">\n                            USVP                            <i class=\"far fa-arrow-right\"><\/i>\n                        <\/a>\n                                    <\/div>\n            <\/div>\n                    <div class=\"personListBlok__item\">\n                <div class=\"sectionHeading__content\">\n                    <h4 class=\"personCardsBlok__name\">Robert O&rsquo;Holla<\/h4>\n                    <p class=\"personCardsBlok__position\">Partenaire d\u2019exploitation<\/p>\n\n                                            <a class=\"personListBlok__link\" href=\"https:\/\/www.endeavourvision.com\/\" target=\"_blank\">\n                            Endeavour Vision                            <i class=\"far fa-arrow-right\"><\/i>\n                        <\/a>\n                                    <\/div>\n            <\/div>\n                    <div class=\"personListBlok__item\">\n                <div class=\"sectionHeading__content\">\n                    <h4 class=\"personCardsBlok__name\">Gary Rieschel<\/h4>\n                    <p class=\"personCardsBlok__position\">Associ\u00e9 g\u00e9rant et fondateur<\/p>\n\n                                            <a class=\"personListBlok__link\" href=\"https:\/\/www.qimingvc.com\/en\/team\/gary-rieschel\" target=\"_blank\">\n                            Qiming Venture Partners                            <i class=\"far fa-arrow-right\"><\/i>\n                        <\/a>\n                                    <\/div>\n            <\/div>\n                    <div class=\"personListBlok__item\">\n                <div class=\"sectionHeading__content\">\n                    <h4 class=\"personCardsBlok__name\">Mike Carusi<\/h4>\n                    <p class=\"personCardsBlok__position\">Partenaire associ\u00e9<\/p>\n\n                                            <a class=\"personListBlok__link\" href=\"https:\/\/www.atvcapital.com\/\" target=\"_blank\">\n                            Advanced Technology Ventures                            <i class=\"far fa-arrow-right\"><\/i>\n                        <\/a>\n                                    <\/div>\n            <\/div>\n                    <div class=\"personListBlok__item\">\n                <div class=\"sectionHeading__content\">\n                    <h4 class=\"personCardsBlok__name\">Hank Plain<\/h4>\n                    <p class=\"personCardsBlok__position\">Partenaire<\/p>\n\n                                            <a class=\"personListBlok__link\" href=\"http:\/\/www.morgenthaler.com\/life-sciences\/team\/hank-plain\/\" target=\"_blank\">\n                            Morgenthaler Ventures                            <i class=\"far fa-arrow-right\"><\/i>\n                        <\/a>\n                                    <\/div>\n            <\/div>\n                    <div class=\"personListBlok__item\">\n                <div class=\"sectionHeading__content\">\n                    <h4 class=\"personCardsBlok__name\">Tim Herbert<\/h4>\n                    <p class=\"personCardsBlok__position\">Pr\u00e9sident et PDG<\/p>\n\n                                            <a class=\"personListBlok__link\" href=\"https:\/\/www.inspiresleep.com\/leadership\/\" target=\"_blank\">\n                            Inspire Medical Systems                            <i class=\"far fa-arrow-right\"><\/i>\n                        <\/a>\n                                    <\/div>\n            <\/div>\n                    <div class=\"personListBlok__item\">\n                <div class=\"sectionHeading__content\">\n                    <h4 class=\"personCardsBlok__name\">Dave Van Meter <\/h4>\n                    <p class=\"personCardsBlok__position\">Partenaire de capital-risque<\/p>\n\n                                            <a class=\"personListBlok__link\" href=\"https:\/\/www.vertexventureshc.com\/#team\" target=\"_blank\">\n                            Vertex Venture Management                            <i class=\"far fa-arrow-right\"><\/i>\n                        <\/a>\n                                    <\/div>\n            <\/div>\n                    <div class=\"personListBlok__item\">\n                <div class=\"sectionHeading__content\">\n                    <h4 class=\"personCardsBlok__name\">Dennis Wahr, M.D.<\/h4>\n                    <p class=\"personCardsBlok__position\">Pr\u00e9sident et PDG<\/p>\n\n                                    <\/div>\n            <\/div>\n        \n    <\/div>\n<\/div>\n<\/div><!-- Nuvaira Block End -->","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-525","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Qui sommes-nous - Nuvaira<\/title>\n<meta name=\"description\" content=\"Nuvaira d\u00e9veloppe des traitements innovants et r\u00e9volutionnaires qui visent \u00e0 am\u00e9liorer la vie des personnes atteintes de maladies pulmonaires obstructives pr\u00e9sentes chez plus de 65 millions d\u2019individus dans le monde entier.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nuvaira.com\/fr\/about-us\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Qui sommes-nous - Nuvaira\" \/>\n<meta property=\"og:description\" content=\"Nuvaira d\u00e9veloppe des traitements innovants et r\u00e9volutionnaires qui visent \u00e0 am\u00e9liorer la vie des personnes atteintes de maladies pulmonaires obstructives pr\u00e9sentes chez plus de 65 millions d\u2019individus dans le monde entier.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nuvaira.com\/fr\/about-us\/\" \/>\n<meta property=\"og:site_name\" content=\"Nuvaira\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-29T15:27:15+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nuvaira.com\\\/fr\\\/about-us\\\/\",\"url\":\"https:\\\/\\\/nuvaira.com\\\/fr\\\/about-us\\\/\",\"name\":\"Qui sommes-nous - Nuvaira\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nuvaira.com\\\/fr\\\/#website\"},\"datePublished\":\"2022-04-22T00:03:20+00:00\",\"dateModified\":\"2023-03-29T15:27:15+00:00\",\"description\":\"Nuvaira d\u00e9veloppe des traitements innovants et r\u00e9volutionnaires qui visent \u00e0 am\u00e9liorer la vie des personnes atteintes de maladies pulmonaires obstructives pr\u00e9sentes chez plus de 65 millions d\u2019individus dans le monde entier.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nuvaira.com\\\/fr\\\/about-us\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nuvaira.com\\\/fr\\\/about-us\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nuvaira.com\\\/fr\\\/about-us\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nuvaira.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Qui sommes-nous\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nuvaira.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/nuvaira.com\\\/fr\\\/\",\"name\":\"Nuvaira\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nuvaira.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Qui sommes-nous - Nuvaira","description":"Nuvaira d\u00e9veloppe des traitements innovants et r\u00e9volutionnaires qui visent \u00e0 am\u00e9liorer la vie des personnes atteintes de maladies pulmonaires obstructives pr\u00e9sentes chez plus de 65 millions d\u2019individus dans le monde entier.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nuvaira.com\/fr\/about-us\/","og_locale":"fr_FR","og_type":"article","og_title":"Qui sommes-nous - Nuvaira","og_description":"Nuvaira d\u00e9veloppe des traitements innovants et r\u00e9volutionnaires qui visent \u00e0 am\u00e9liorer la vie des personnes atteintes de maladies pulmonaires obstructives pr\u00e9sentes chez plus de 65 millions d\u2019individus dans le monde entier.","og_url":"https:\/\/nuvaira.com\/fr\/about-us\/","og_site_name":"Nuvaira","article_modified_time":"2023-03-29T15:27:15+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nuvaira.com\/fr\/about-us\/","url":"https:\/\/nuvaira.com\/fr\/about-us\/","name":"Qui sommes-nous - Nuvaira","isPartOf":{"@id":"https:\/\/nuvaira.com\/fr\/#website"},"datePublished":"2022-04-22T00:03:20+00:00","dateModified":"2023-03-29T15:27:15+00:00","description":"Nuvaira d\u00e9veloppe des traitements innovants et r\u00e9volutionnaires qui visent \u00e0 am\u00e9liorer la vie des personnes atteintes de maladies pulmonaires obstructives pr\u00e9sentes chez plus de 65 millions d\u2019individus dans le monde entier.","breadcrumb":{"@id":"https:\/\/nuvaira.com\/fr\/about-us\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nuvaira.com\/fr\/about-us\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nuvaira.com\/fr\/about-us\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nuvaira.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Qui sommes-nous"}]},{"@type":"WebSite","@id":"https:\/\/nuvaira.com\/fr\/#website","url":"https:\/\/nuvaira.com\/fr\/","name":"Nuvaira","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nuvaira.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/nuvaira.com\/fr\/wp-json\/wp\/v2\/pages\/525","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nuvaira.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/nuvaira.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/nuvaira.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nuvaira.com\/fr\/wp-json\/wp\/v2\/comments?post=525"}],"version-history":[{"count":0,"href":"https:\/\/nuvaira.com\/fr\/wp-json\/wp\/v2\/pages\/525\/revisions"}],"wp:attachment":[{"href":"https:\/\/nuvaira.com\/fr\/wp-json\/wp\/v2\/media?parent=525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}